Adial Pharmaceuticals Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 0.56
Market capitalization 6.96M
Operating cash flow -11.81M
ESG Scores unknown

Company description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -190.54k 90.53k 624.79k -353.77k
Total Cashflows From Investing Activities -350k -350k -350k -34.02k
Net Borrowings -75k
Total Cash From Financing Activities 6.35M 9.25M 5.61M 13.64M
Change To Operating Activities -658.77k 117.64k 620.23k 1.82M
Issuance Of Stock 7.48M 10.3M 6.17M 13.64M
Net Income -11.63M -8.59M -10.89M -19.42M
Change In Cash 3.85M 2.91M -2.38M 1.66M
Effect Of Exchange Rate
Total Cash From Operating Activities -2.5M -6.34M -7.63M -11.95M
Depreciation 563 565 564 55.11k
Change To Account Receivables
Other Cashflows From Financing Activities -1.05M -1.05M -559.78k
Change To Netincome 9.63M 2.04M 2.01M 5.95M
Capital Expenditures -64.61k -64.61k -64.61k -64.61k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 368.46k 3.97M 5.85M 8.4M
Income Before Tax -11.63M -8.59M -10.89M -19.52M
Net Income -11.63M -8.59M -10.89M -19.42M
Selling General Administrative 1.72M 4.28M 5.07M 9.3M
Gross Profit
Ebit -2.09M -8.24M -10.93M -17.69M
Operating Income -2.09M -8.24M -10.93M -17.69M
Interest Expense -1.17M
Income Tax Expense -94.08k
Total Revenue
Cost Of Revenue
Total Other Income ExpenseNet -9.54M -346.53k 34.99k -1.82M
Net Income From Continuing Ops -11.63M -8.59M -10.89M -19.42M
Net Income Applicable To Common Shares -11.63M -8.59M -10.89M -19.42M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 257.97k 539.05k 1.51M 3.97M
Total Stockholder Equity 4.44M 7.14M 3.99M 3.51M
Other Current Liabilities 9.68k
Total Assets 4.7M 7.68M 5.49M 7.47M
Common Stock 6.86k 10.37k 14.39k 20.95k
Other Current Assets 505.96k 536.92k 233.03k 9.93k
Retained Earnings -12.04M -20.63M -31.52M -50.94M
Treasury Stock
Cash 3.87M 6.78M 4.4M 6.06M
Total Current Liabilities 257.97k 539.05k 1.51M 2.72M
Other Stockholder Equity
Property, Plant, and Equipment 304.36k
Total Current Assets 4.69M 7.67M 5.14M 6.46M
Net Tangible Assets 4.43M 7.13M 3.98M 2.8M
Net Receivables
Accounts Payable 99.67k 190.2k 648.74k 286.19k


Insider Transactions

Here are the insider transactions of stock shares related to Adial Pharmaceuticals Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
CLAIBORNE CARY JStock Award(Grant) at price 0.42 - 0.43 per share.D2022-09-20Chief Executive Officer100k
CLAIBORNE CARY JStock Award(Grant) at price 0.00 per share.D2022-08-18Chief Executive Officer1M
STILLEY WILLIAM B. IIIStock Award(Grant) at price 0.00 per share.D2022-02-23Chief Executive Officer250k
NEWMAN JAMES W. JR.Purchase at price 2.66 - 2.72 per share.D/I2021-12-30Director25k
SCHUYLER KEVINStock Gift at price 0.00 per share.D2021-12-23Director and Beneficial Owner of more than 10% of a Class of Security312.99k
STILLEY WILLIAM B. IIIPurchase at price 2.59 - 2.75 per share.D2021-11-30Chief Executive Officer20.6k
NEWMAN JAMES W. JR.Purchase at price 2.85 per share.I2021-11-26Director10k
JOHNSON BANKOLE ASale at price 3.76 per share.I2021-10-04Officer200k
JOHNSON BANKOLE ASale at price 2.50 per share.I2021-04-06Officer150k
STILLEY WILLIAM B. IIIStock Award(Grant) at price 0.00 per share.D2021-01-26Chief Executive Officer201.11k
NEWMAN JAMES W. JR.Stock Award(Grant) at price 0.00 per share.I2021-01-26Director3.73k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Adial Pharmaceuticals Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Adial Pharmaceuticals Inc

Here is the result of two systematic investment strategies applied to Adial Pharmaceuticals Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Adial Pharmaceuticals Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Adial Pharmaceuticals Inc:

Adial Pharmaceuticals Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 41.27% on the backtest period.

Performance at glance

Performance

41.27 %

Latent gain

723.05 $

Invested capital

1751.95 $

Annualized return

12.07 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Adial Pharmaceuticals Inc

This is the result of two momentum investment strategies applied to Adial Pharmaceuticals Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Adial Pharmaceuticals Inc

The following chart shows all the entries opened by the momentum investment system on Adial Pharmaceuticals Inc:

Adial Pharmaceuticals Inc momentum entries
  • The first momentum investment strategy would give 78.68% of return on Adial Pharmaceuticals Inc. That represents 2951.26$ of latent gain with 3750.74$ of employed capital.
  • The second momentum investment strategy would give 62.59% of return on Adial Pharmaceuticals Inc. That represents 1878.95$ of latent gain with 3002.05$ of employed capital.
Performance at glance (1Q Momentum)

Performance

78.68 %

Latent gain

2951.26 $

Invested capital

3750.74 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

62.59 %

Latent gain

1878.95 $

Invested capital

3002.05 $

Annualized return

21.29 %

Momentum equity curve on Adial Pharmaceuticals Inc

The following chart shows the equity curve of the two momentum strategies applied to Adial Pharmaceuticals Inc:

Adial Pharmaceuticals Inc momentum equity

Note: the dividends potentially given by Adial Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Adial Pharmaceuticals Inc

The following chart shows the employed capital evolution of the two momentum strategies on Adial Pharmaceuticals Inc since the beginning:

Adial Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Adial Pharmaceuticals Inc

Buy the dip entry openings on Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc

The performance achieved by the robo-advisor on Adial Pharmaceuticals Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Adial Pharmaceuticals Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Adial Pharmaceuticals Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Adial Pharmaceuticals Inc

The following chart shows the result of the investment strategy applied to Adial Pharmaceuticals Inc:

Adial Pharmaceuticals Inc

Note: the dividends potentially given by Adial Pharmaceuticals Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Adial Pharmaceuticals Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Adial Pharmaceuticals Inc:

Adial Pharmaceuticals Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Adial Pharmaceuticals Inc

In this section, I will compare the three previous investment strategies applied to Adial Pharmaceuticals Inc.

Equity curve comparison on Adial Pharmaceuticals Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Adial Pharmaceuticals Inc investment strategy comparison

Employed capital comparison on Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc investment comparison

Performance comparison on Adial Pharmaceuticals Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 41.27% 723.05$ 1751.95$ 12.07%
Momentum 1 quarter 78.68% 2951.26$ 3750.74$ 24.74%
Momentum 2 quarters 62.59% 1878.95$ 3002.05$ 21.29%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

12.07 %

Momentum 1Q

21.29 %

Momentum 2Q

21.29 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Adial Pharmaceuticals Inc:


Company information

Company name Adial Pharmaceuticals Inc
Country United States
City Charlottesville
Address 1180 Seminole Trail
Phone 434 422 9800
Website www.adialpharma.com
FullTime employees 16
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker ADIL
Market www.nasdaq.com

Adial Pharmaceuticals Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown